Signal Transduction and Targeted Therapy

Signal Transduction and Targeted Therapy is an open-access journal published by Springer Nature in the United Kingdom. OpenAlex counts 3,081 works from it, cited 394,034 times; its h-index is 315. Its two-year mean citedness, which is computed the way the impact factor is, is 63.07: a paper it published in the two years before was cited about 63.07 times last year. It published 428 papers in 2025, up 15% from 372 in 2024. Its article processing charge is about US$3,790.

Publisher
Springer Nature
Citations per paper
63.07 two-year mean, OpenAlex
h-index
315 i10-index 2,032
Access
Open access · in DOAJ
APC
US$3,790
ISSN
2059-3635, 2095-9907
Country
United Kingdom
Works published
3,081 cited 394,034 times
Papers in 2025
428
Field
Medicine
Website
Journal home ↗

Signal Transduction and Targeted Therapy year by year

Papers it published each year, and the citations all its papers received that year.

YearPapers publishedCitations received
2026 so far509123,200
2025428111,193
202437269,117
202346740,092
202240325,943
202144215,436
20203016,204
2019661,672

What Signal Transduction and Targeted Therapy publishes

Its most frequent research topics, by OpenAlex's topic classification.

Questions about Signal Transduction and Targeted Therapy

What is the impact factor of Signal Transduction and Targeted Therapy?

Clarivate's Journal Impact Factor is licensed and not shown here. OpenAlex's two-year mean citedness, computed the same way from open data, is 63.07 for Signal Transduction and Targeted Therapy: on average, each paper it published in the two years before was cited about 63.07 times in a year.

What is the h-index of Signal Transduction and Targeted Therapy?

315, by OpenAlex's count: 315 of its papers have each been cited at least 315 times. Its i10-index is 2,032.

Is Signal Transduction and Targeted Therapy open access?

Yes. OpenAlex lists Signal Transduction and Targeted Therapy as an open-access journal: its papers are free to read. It is also listed in the Directory of Open Access Journals (DOAJ).

What is the publication fee (APC) of Signal Transduction and Targeted Therapy?

About US$3,790, which is its article processing charge (APC) as listed by OpenAlex. Fees change and waivers exist, so check the journal's own page before you submit.

What is the ISSN of Signal Transduction and Targeted Therapy?

Its linking ISSN is 2059-3635; all its ISSNs: 2059-3635, 2095-9907.

Who publishes Signal Transduction and Targeted Therapy?

Springer Nature, based in the United Kingdom.

How many papers does Signal Transduction and Targeted Therapy publish a year?

428 in 2025, by OpenAlex's count of what it published that year.

What does Signal Transduction and Targeted Therapy publish?

Its most frequent research topics are SARS-CoV-2 and COVID-19 Research, Cancer Immunotherapy and Biomarkers, COVID-19 Clinical Research Studies, in the field of Medicine.

Is Signal Transduction and Targeted Therapy a predatory journal?

Nothing in the scholarly indexes suggests so. Signal Transduction and Targeted Therapy is on OpenAlex's list of core sources, journals with peer review and an editorial board, it has published 3,081 works cited 394,034 times, and it is listed in DOAJ. For a journal you do not know, check the red flags with our predatory journal checker.

Is Signal Transduction and Targeted Therapy indexed in Scopus or Web of Science?

Check the Scopus Sources list and Clarivate's Master Journal List by its ISSN (2059-3635): both are free to search. Our guide on checking journal indexing shows each step.

Journals like Signal Transduction and Targeted Therapy

Other Medicine journals with a similar impact.

Every Medicine journal, ranked · The journal directory

Journal data from OpenAlex (CC0), compiled 21 November 2026. Download the whole directory as a CSV file (CC BY 4.0).